← Leaderboards
Wenlin Deng
Rxbio, Inc.
$1,025,784
Attributed
$1,025,784
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $500K · FY2007–11$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,025,784 · 3
By mechanism
RC1$731,010 · 1
N43$194,797 · 1
R43$99,977 · 1
Top collaborators
No co-investigators on record.
Most similar at Rxbio, Inc.
Same institution · by research overlap
- Shannon McCool$9,652,330
- Veeresh Gududuru$97,162
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCancer PatientMedicalRadiationGastrointestinalPublic Health Medicine (Field)Gastrointestinal Tract StructureNuclearRouteVillusGastrointestinal InjurySourceLifeRecoveryAcuteEvaluationDl-Alpha-DifluoromethylornithineBone MarrowExposure ToMucous MembraneBioshieldLethal Dose 50IrradiationBacterial Translocation
Grant awards (4)
TAS::75 0849::TAS$194,797
N43 · FY2011 · CA · contact PI
Radioprotective / Radiomitigating Efficacy of Rx100 in the Gastrointestinal Tract$231,011
RC1 · FY2009 · AI · contact PI
Development of an LPA receptor modulator Rx100 as a radioprotectant$99,977
R43 · FY2008 · CA · contact PI
Radioprotective / Radiomitigating Efficacy of Rx100 in the Gastrointestinal Tract$499,999
RC1 · FY2007 · AI · contact PI